RJFSA
SRPT icon

Raymond James Financial Services Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$973K Buy
7,787
+74
+1% +$10.2K ﹤0.01% 2185
2024
Q2 		$1.22M Sell
7,713
-1,371
-15% -$176K ﹤0.01% 1964
2024
Q1 		$1.18M Buy
9,084
+109
+1% +$13.4K ﹤0.01% 1963
2023
Q4 		$865K Sell
8,975
-974
-10% -$93.4K ﹤0.01% 2074
2023
Q3 		$1.21M Sell
9,949
-463
-4% -$52.3K ﹤0.01% 1796
2023
Q2 		$1.19M Buy
10,412
+1,012
+11% +$130K ﹤0.01% 1808
2023
Q1 		$1.3M Sell
9,400
-6,267
-40% -$813K ﹤0.01% 1743
2022
Q4 		$2.03M Buy
15,667
+4,036
+35% +$468K ﹤0.01% 1435
2022
Q3 		$1.29M Sell
11,631
-1,012
-8% -$102K ﹤0.01% 1679
2022
Q2 		$948K Buy
12,643
+2,806
+29% +$206K ﹤0.01% 1874
2022
Q1 		$768K Sell
9,837
-555
-5% -$42.5K ﹤0.01% 2120
2021
Q4 		$936K Sell
10,392
-12,132
-54% -$1.04M ﹤0.01% 2011
2021
Q3 		$2.08M Sell
22,524
-8,666
-28% -$668K ﹤0.01% 1467
2021
Q2 		$2.42M Buy
31,190
+572
+2% +$43.4K ﹤0.01% 1363
2021
Q1 		$2.28M Buy
30,618
+18,301
+149% +$1.69M 0.01% 1325
2020
Q4 		$2.1M Buy
12,317
+310
+3% +$45.9K 0.01% 1265
2020
Q3 		$1.69M Buy
12,007
+870
+8% +$132K ﹤0.01% 1259
2020
Q2 		$1.79M Sell
11,137
-792
-7% -$108K 0.01% 1167
2020
Q1 		$1.17M Sell
11,929
-1,720
-13% -$197K 0.01% 1123
2019
Q4 		$1.76M Sell
13,649
-1,770
-11% -$179K 0.01% 1226
2019
Q3 		$1.16M Sell
15,419
-346
-2% -$40.9K ﹤0.01% 1384
2019
Q2 		$2.4M Sell
15,765
-1,389
-8% -$169K 0.01% 1004
2019
Q1 		$2.04M Buy
17,154
+4,642
+37% +$597K 0.01% 1057
2018
Q4 		$1.36M Buy
12,512
+852
+7% +$107K 0.01% 1109
2018
Q3 		$1.88M Sell
11,660
-592
-5% -$80.9K 0.01% 1117
2018
Q2 		$1.62M Buy
12,252
+131
+1% +$12.4K 0.01% 1144
2018
Q1 		$898K Sell
12,121
-6,518
-35% -$435K 0.01% 1370
2017
Q4 		$1.04M Sell
18,639
-8,957
-32% -$475K 0.01% 1281
2017
Q3 		$1.25M Buy
27,596
+6,725
+32% +$269K 0.01% 1163
2017
Q2 		$704K Buy
20,871
+9,635
+86% +$314K ﹤0.01% 1478
2017
Q1 		$333K Buy
11,236
+3,173
+39% +$98.2K ﹤0.01% 1837
2016
Q4 		$221K Sell
8,063
-2,898
-26% -$116K ﹤0.01% 1999
2016
Q3 		$673K Buy
+10,961
New +$331K 0.01% 1328

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Raymond James Financial Services Advisors's SRPT Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Sarepta Therapeutics (SRPT) stake by 0.96% in Q3 2024, buying an estimated $10.2K and bringing the position to 7,787 shares worth $973K. The position accounts for ﹤0.01% of the portfolio, ranked #2185.

Raymond James Financial Services Advisors first reported a position in SRPT in Q3 2016 and has held it in 33 quarters since. The position peaked at $2.42M in Q2 2021. 458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Raymond James Financial Services Advisors held 7,787 shares of Sarepta Therapeutics worth $973K as of Q3 2024.
  • Raymond James Financial Services Advisors bought 74 Sarepta Therapeutics shares in Q3 2024, an estimated $10.2K.
  • Sarepta Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2185 holding.
  • Raymond James Financial Services Advisors first reported a position in Sarepta Therapeutics in Q3 2016 and has held it in 33 quarters since.
  • Raymond James Financial Services Advisors's Sarepta Therapeutics position peaked at $2.42M in Q2 2021.
  • 458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.